**Qualitative and quantitative composition of the medicinal product**

**active ingredients**

1 *Ospolot*® film-coated tablet contains 200 mg sulthiame

**other ingredients**

*Ospolot*®

Gelatin, hypromellose, lactose, macrogol, magnesium stearate, maize starch, silicon dioxide, talcum, titanium dioxide (E 171).

**Pharmaceutical form**

film-coated tablet

**Data on pharmacological properties, pharmacokinetics and bioavailability which are necessary for therapeutic use**

**Pharmacological properties**

Sulthiame is classified as a carboanhydrase inhibitor and displays an anticonvulsant effect in the electroconvulsion test (rat and mouse) and in the convulsion test with pentamethylene tetrazole (mouse).

**Pharmacokinetics**

*Absorption, plasma levels*

After oral administration, sulthiame is rapidly and completely absorbed, preferentially from the upper section of the small intestine. Maximum plasma concentrations are measured after 1 - 5 hours.

*Distribution, plasma protein binding*

About 29% of the active ingredient is bound to plasma proteins.

*Metabolism, elimination*

80 to 90% is eliminated with the urine, and 10 to 20% with the faeces after biliary secretion. Within 24 hours, 32% of the administered dose are eliminated unchanged via the kidneys.

**Clinical particulars**

**Therapeutic indications**

Epileptic seizures of focal origin with or without secondary generalisation, especially benign partial epilepsies in childhood, such as rolandic epilepsy, pseudo-Lennox syndrome, bioelectric status epilepticus in non-REM sleep (ESES), Landau-Kleffner syndrome.

**Contraindications**

*Ospolot*® may not be administered in the case of known hypersensitivity to sulthiame, other sulphonamides or other constituents of the drug.
Sulthiame should not be administered
in patients with a history of acute porphyria
in patients with hyperthyroidism or arterial hypertension.

Side effects
Gastric complaints can occur in about 10% of patients.
The following side effects occasionally occur dose-dependent: paraesthesias in the extremities
and in the face, tachypnoea, hyperpnoea, dyspnoea, dizziness, headache, stenocardia,
tachycardia, double vision, singultus, weight loss or lack of appetite.
In rare cases, hallucinations, anxiety, myasthenic phenomena, lack of drive, joint pain, a
grand mal state or increased seizure activity can be triggered.
In individual cases, it has been suspected that sulthiame may be associated with the induction
of acute renal failure, Stevens-Johnson syndrome, Lyell's syndrome, or polyneuritis.
In one case, the administration of Ospolot® led to progressive weakness of the limbs,
hypersalivation, slurred speech, increasing drowsiness up to coma. The symptoms abated
within hours of Ospolot® being discontinued.

Special warnings and precautions for use
Sulthiame should not be administered, or only administered with special caution in
in patients with impaired renal function
in patients with a history of psychiatric diseases.

Note:
The patient and his or her parents should be told to consult the attending doctor immediately
if fever, sore throat, allergic skin reactions with lymph node swelling and/or flu-like
symptoms occur during treatment with Ospolot®. Due to the potential side effects and allergic
reactions mentioned, the blood count and renal function must be regularly monitored.
Progressive thrombopenias or leucopenias that are accompanied by clinical symptoms, such
as fever or sore throat, necessitate that treatment be interrupted. In the event of severe allergic
reactions, Ospolot® must be discontinued immediately. Treatment should also be interrupted
if a lasting increase in creatinine occurs.

Use in pregnancy and lactation
Ospolot® may not be used during pregnancy and lactation, as no investigations are available
on safety for this period.

Interaction with other medicinal products and other forms of interaction
If sulthiame is combined with phenytoin, the plasma levels of phenytoin can be markedly
elevated. This combination requires especially strict monitoring and frequent controls of the
phenytoin plasma levels, particularly in the case of impaired renal function. In combination
with lamotrigine, an elevation of lamotrigine levels in the blood has also been observed in
individual cases. Therefore, lamotrigine levels should be checked more frequently at the
beginning of such a treatment.
If sulthiame is combined with primidone, the intensity of the side effects of sulthiame may
increase; especially in children, dizziness, uncertain gait and drowsiness can occur. During
treatment with sulthiame, the patient should abstain from alcohol, since sulphonamides have
an effect similar to that of disulfiram, and sulthiame, as a sulphonamide derivative, can theoretically have a similar effect. These symptoms include a very unpleasant, although generally self-limiting systemic reaction caused by vasodilatation, with pulsating headache, respiratory depression, nausea, vomiting, tachycardia, hypotension, amblyopia, confusion, shock reactions, arrhythmias, loss of consciousness and seizures. The degree and duration of these symptoms can vary to a great extent.

**Posology and method of administration**
The dosage must be established and monitored by the doctor on an individual basis. The maintenance dose is about 5 to 10 mg/kg body weight per day. It should be build up step-wise (tapered in) over a one-week period. *Ospolot®* film-coated tablets have a dose notch. Due to the short half-life of sulthiame, the daily dose should as far as possible be spread over three single doses. If the daily dose is spread over the day in this way, constant plasma levels are to be expected after five to six days. Therapeutic plasma concentrations of sulthiame have not yet been determined.

**Administration**
The film-coated tablets are to be taken unchewed with plenty of liquid (roughly one glass of water), as far as possible spread over 3 single doses. A change from another medication or to combination treatment must be done gradually. *Ospolot®* should not be discontinued abruptly. A neuropaediatrician experienced in treating epilepsy should decide on dose adjustment, the duration of treatment and discontinuation on an individual basis. If therapy is not successful, treatment with sulthiame should be discontinued after about one to two months. It is recommendable to monitor the blood count and renal function parameters before treatment with *Ospolot®*, then at weekly intervals in the first month of treatment, and thereafter at monthly intervals. After six months' treatment, checks every three to six months are sufficient.

**Overdose**
**Symptoms of intoxication**
Headache, dizziness, ataxia, impaired consciousness, metabolic acidosis, crystals in the urine. Sulthiame has a low toxicity, overdoses of 4 to 5 g sulthiame have been survived. The intake of around 20 g sulthiame by adults with the intention of committing suicide was fatal in one case. In another case, the patient made a full recovery.

b) **Therapy of intoxications**
A specific antidote is not known. The standard measures (gastric lavage and active charcoal) for minimising absorption and for maintaining vital functions should be taken. Sodium bicarbonate can be infused to treat acidosis. Alkalising diuretic therapy is recommended for preventing renal damage and crystalluria.

**Effects on ability to drive and use machines**
Even when used as directed, these drugs can affect reactions to such an extent - especially at the start of treatment - that the ability to drive a vehicle or operate machinery may be impaired. This applies to a greater extent in combination with alcohol.
Pharmaceutical information
Incompatibilities
None known.

Shelf-life
*Ospol®* has a shelf-life of 3 years.
These drugs should not be used after their expiry date (see folding box).

Special precautions for storage
None.

Dosage forms and pack sizes
Pack of 50 film-coated tablets

Manufacturer
DESITIN ARZNEIMITTEL GmbH
Weg beim Jäger 214
D-22335 Hamburg
Germany

Sole Agent for the Manufacturer
Megapharm Ltd.
POB 519 Hod Hasharon
45105 Israel